Quantitative proteomics reveals unique responses to antimicrobial treatments in clinical Pseudomonas aeruginosa isolates

mSystems. 2023 Oct 26;8(5):e0049123. doi: 10.1128/msystems.00491-23. Epub 2023 Aug 25.

Abstract

Pseudomonas aeruginosa is an important pathogen often associated with hospital-acquired infections and chronic lung infections in people with cystic fibrosis. P. aeruginosa possesses a wide array of intrinsic and adaptive mechanisms of antibiotic resistance, and the regulation of these mechanisms is complex. Label-free quantitative proteomics is a powerful tool to compare susceptible and resistant strains of bacteria and their responses to antibiotic treatments. Here we compare the proteomes of three isolates of P. aeruginosa with different antibiotic resistance profiles in response to five challenge conditions. We uncover unique and shared proteome changes for the widely used laboratory strain PAO1 and two isolates of the Liverpool epidemic strain of P. aeruginosa, LESlike1 and LESB58. Our data set provides insight into antibiotic resistance in clinically relevant Pseudomonas isolates and highlights proteins, including those with uncharacterized functions, which can be further investigated for their role in adaptive responses to antibiotic treatments.

Keywords: Liverpool epidemic strain; Pseudomonas aeruginosa; antibiotics; label-free quantitative proteomics.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cystic Fibrosis* / drug therapy
  • Humans
  • Proteome
  • Proteomics
  • Pseudomonas Infections* / drug therapy
  • Pseudomonas aeruginosa

Substances

  • Anti-Bacterial Agents
  • Proteome